

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Johnson Brady</u> _____ (Last) (First) (Middle) <u>6310 NANCY RIDGE DRIVE</u> _____ (Street) <u>SAN CA 92121</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/09/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Cidara Therapeutics, Inc. [CDTX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Vice President, Finance</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,369	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	12/17/2026	Common Stock	12,111	2.45	D	
Stock Option (right to buy)	(2)	12/17/2026	Common Stock	20,012	2.45	D	
Stock Option (right to buy)	(3)	03/18/2030	Common Stock	6,700	1.98	D	
Stock Option (right to buy)	(4)	03/16/2031	Common Stock	12,150	2.55	D	
Restricted Stock Unit	(5)	(5)	Common Stock	524	(6)	D	

Explanation of Responses:

- One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.
- Shares are fully vested
- The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.
- The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.
- The shares shall vest upon the achievement of various clinical and corporate milestones.
- Restricted stock units convert into common stock on a one-for-one basis.

Remarks:

/s/ Brady Johnson

07/19/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.